T7 Peptide-modified macrophage membrane-coated nanoplatform for enhanced glioma treatment

[Display omitted] The efficient and secure delivery of intravenous chemotherapeutic agents across the blood–brain barrier (BBB) to the precise location of a brain tumor is a crucial element in glioma treatment. Herein, we introduce a biomimetic nanoplatform (T7-M-C/S) comprising a core made up of ir...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2024-11, Vol.204, p.114527, Article 114527
Main Authors: Sun, Xuanrong, Xie, Dehui, Lou, Zhao, Zhou, Yujie, Li, Ming, Li, Qingyong, Cai, Yue
Format: Article
Language:English
Subjects:
BBB penetration
Biomimetic nanoplatform
Glioma therapy
Macrophage membrane
T7 peptide
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The efficient and secure delivery of intravenous chemotherapeutic agents across the blood–brain barrier (BBB) to the precise location of a brain tumor is a crucial element in glioma treatment. Herein, we introduce a biomimetic nanoplatform (T7-M-C/S) comprising a core made up of irinotecan hydrochloride (CPT11) and its bioactive metabolite, 7-Ethyl-10-hydroxycamptothecin (SN38), surrounded by a layer of T7-peptide-modified macrophage membrane. CPT11 spontaneously assembles with SN38 into stable and water-dispersible nanoparticles (C/S), greatly enhancing the water solubility of SN38. The integration of the modified peptide with the inherent proteins expressed by macrophage cells confers the nanoplatform with enhanced bioavailability and robust glioma-targeting abilities, ultimately resulting in superior therapeutic outcomes. These discoveries highlight a drug delivery system characterized by a high drug loading capacity, leveraging the macrophage membrane, and promising significant potential for glioma treatment.
ISSN:0939-6411
1873-3441
1873-3441
DOI:10.1016/j.ejpb.2024.114527